Skip to main content
. 2012 Apr 4;55(2):279–290. doi: 10.1093/cid/cis382

Figure 3.

Figure 3.

A 2-way sensitivity analysis of the cost-effectiveness of screening for acute hepatitis C virus (HCV) infection as a function of HCV incidence and the probability of attaining sustained virologic response (SVR) with treatment for chronic HCV. The figure illustrates the optimal strategy for screening for acute HCV infection, with various efficacies of new agents for treating HCV infection and different HCV infection incidence rates, assuming that 86% of those treated for acute HCV infection attain SVR. The shade of the graph at the point of intersection corresponding to a given HCV incidence and chronic HCV therapeutic efficacy illustrates the optimal screening strategy, assuming a societal willingness to pay of $100 000 per quality-adjusted life-year gained. Abbreviations: Ab, antibody; HCV, hepatitis C virus; LFT, liver function test; NEAT, European AIDS Treatment Network; SVR, sustained virologic response.